Literature DB >> 22252870

Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.

Nathan C Miller1, Lauriane E Quenee, Derek Elli, Nancy A Ciletti, Olaf Schneewind.   

Abstract

Current efforts to develop plague vaccines focus on LcrV, a polypeptide that resides at the tip of type III secretion needles. LcrV-specific antibodies block Yersinia pestis type III injection of Yop effectors into host immune cells, thereby enabling phagocytes to kill the invading pathogen. Earlier work reported that antibodies against Y. pestis LcrV cannot block type III injection by Yersinia enterocolitica strains and suggested that lcrV polymorphisms may provide for escape from LcrV-mediated plague immunity. We show here that polyclonal or monoclonal antibodies raised against Y. pestis KIM D27 LcrV (LcrV(D27)) bind LcrV from Y. enterocolitica O:9 strain W22703 (LcrV(W22703)) or O:8 strain WA-314 (LcrV(WA-314)) but are otherwise unable to block type III injection by Y. enterocolitica strains. Replacing the lcrV gene on the pCD1 virulence plasmid of Y. pestis KIM D27 with either lcrV(W22703) or lcrV(WA-314) does not affect the ability of plague bacteria to secrete proteins via the type III pathway, to inject Yops into macrophages, or to cause lethal plague infections in mice. LcrV(D27)-specific antibodies blocked type III injection by Y. pestis expressing lcrV(W22703) or lcrV(WA-314) and protected mice against intravenous lethal plague challenge with these strains. Thus, although antibodies raised against LcrV(D27) are unable to block the type III injection of Y. enterocolitica strains, expression of lcrV(W22703) or lcrV(WA-314) in Y. pestis did not allow these strains to escape LcrV-mediated plague protective immunity in the intravenous challenge model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22252870      PMCID: PMC3318405          DOI: 10.1128/IAI.05637-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

Review 1.  The type III secretion system tip complex and translocon.

Authors:  C A Mueller; P Broz; G R Cornelis
Journal:  Mol Microbiol       Date:  2008-04-08       Impact factor: 3.501

2.  Construction of defined F1 negative mutants of virulent Yersinia pestis.

Authors:  P L Worsham; M P Stein; S L Welkos
Journal:  Contrib Microbiol Immunol       Date:  1995

3.  LcrV plague vaccine with altered immunomodulatory properties.

Authors:  Katie A Overheim; R William Depaolo; Kristin L Debord; Elizabeth M Morrin; Debra M Anderson; Nathaniel M Green; Robert R Brubaker; Bana Jabri; Olaf Schneewind
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Restriction of DNA in Yersinia enterocolitica detected by recipient ability for a derepressed R factor from Escherichia coli.

Authors:  G Cornelis; C Colson
Journal:  J Gen Microbiol       Date:  1975-04

5.  Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.

Authors:  Lauriane E Quenee; Nancy A Ciletti; Derek Elli; Timothy M Hermanas; Olaf Schneewind
Journal:  Vaccine       Date:  2011-07-16       Impact factor: 3.641

6.  Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs.

Authors:  K F Meyer; G Smith; L Foster; M Brookman; M Sung
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

7.  Yersinia pestis LcrV forms a stable complex with LcrG and may have a secretion-related regulatory role in the low-Ca2+ response.

Authors:  M L Nilles; A W Williams; E Skrzypek; S C Straley
Journal:  J Bacteriol       Date:  1997-02       Impact factor: 3.490

8.  Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide.

Authors:  V L Motin; R Nakajima; G B Smirnov; R R Brubaker
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

9.  YopB and YopD constitute a novel class of Yersinia Yop proteins.

Authors:  S Håkansson; T Bergman; J C Vanooteghem; G Cornelis; H Wolf-Watz
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

10.  Function and molecular architecture of the Yersinia injectisome tip complex.

Authors:  Petr Broz; Catherine A Mueller; Shirley A Müller; Ansgar Philippsen; Isabel Sorg; Andreas Engel; Guy R Cornelis
Journal:  Mol Microbiol       Date:  2007-09       Impact factor: 3.501

View more
  9 in total

1.  Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

Authors:  Wei Sun; Shilpa Sanapala; Hannah Rahav; Roy Curtiss
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

2.  A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice.

Authors:  Shannon J Heine; Olga L Franco-Mahecha; Khandra T Sears; Cinthia B Drachenberg; Maarten L van Roosmalen; Kees Leenhouts; Wendy L Picking; Marcela F Pasetti
Journal:  J Immunol       Date:  2019-02-20       Impact factor: 5.422

Review 3.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

4.  LcrV mutants that abolish Yersinia type III injectisome function.

Authors:  Katherine Given Ligtenberg; Nathan C Miller; Anthony Mitchell; Gregory V Plano; Olaf Schneewind
Journal:  J Bacteriol       Date:  2012-12-07       Impact factor: 3.490

5.  Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.

Authors:  Shilpa Sanapala; Hannah Rahav; Hetal Patel; Wei Sun; Roy Curtiss
Journal:  Vaccine       Date:  2016-04-06       Impact factor: 3.641

Review 6.  Plague vaccine: recent progress and prospects.

Authors:  Wei Sun; Amit K Singh
Journal:  NPJ Vaccines       Date:  2019-02-18       Impact factor: 9.399

7.  Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model.

Authors:  Catherine Daniel; Amélie Dewitte; Sabine Poiret; Michaël Marceau; Michel Simonet; Laure Marceau; Guillaume Descombes; Denise Boutillier; Nadia Bennaceur; Sébastien Bontemps-Gallo; Nadine Lemaître; Florent Sebbane
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

Review 8.  Antibodies Inhibiting the Type III Secretion System of Gram-Negative Pathogenic Bacteria.

Authors:  Julia A Hotinger; Aaron E May
Journal:  Antibodies (Basel)       Date:  2020-07-27

9.  Glutathionylation of Yersinia pestis LcrV and Its Effects on Plague Pathogenesis.

Authors:  Anthony Mitchell; Christina Tam; Derek Elli; Thomas Charlton; Patrick Osei-Owusu; Farbod Fazlollahi; Kym F Faull; Olaf Schneewind
Journal:  MBio       Date:  2017-05-16       Impact factor: 7.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.